This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Aceragen 미래 성장
Future 기준 확인 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Aceragen.
주요 정보
n/a
수익 성장률
85.2%
EPS 성장률
| Biotechs 수익 성장 | 24.1% |
| 매출 성장률 | -161.8% |
| 향후 자기자본 수익률 | n/a |
| 애널리스트 커버리지 | Low |
| 마지막 업데이트 | 01 Mar 2023 |
최근 미래 성장 업데이트
Recent updates
Idera Pharmaceuticals completes acquisition of Aceragen
Sep 28We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate
Aug 24
We Think Idera Pharmaceuticals (NASDAQ:IDRA) Needs To Drive Business Growth Carefully
May 11Is Idera Pharmaceuticals (NASDAQ:IDRA) In A Good Position To Deliver On Growth Plans?
Mar 07When Will Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Become Profitable?
Jan 31Idera outlines capital requirement to move tilsotolimod toward commercialization in advanced melanoma
Jan 13Could The Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Ownership Structure Tell Us Something Useful?
Dec 27Don't Ignore The Fact That This Insider Just Sold Some Shares In Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)
Dec 27Idera Pharmaceuticals receives $5M in additional proceeds from private placement
Dec 15We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate
Nov 25Idera Pharma names new operations chief
Nov 17Idera Pharmaceuticals EPS misses by $0.37
Oct 29수익 및 매출 성장 예측
| 날짜 | 수익 | 수익 | 잉여 현금 흐름 | 작전 현금 | 평균 애널리스트 수 |
|---|---|---|---|---|---|
| 12/31/2024 | N/A | -63 | N/A | N/A | 1 |
| 12/31/2023 | N/A | N/A | N/A | N/A | 1 |
| 3/31/2023 | 7 | -41 | -30 | -30 | N/A |
| 12/31/2022 | 5 | -23 | -24 | -24 | N/A |
| 9/30/2022 | 0 | -16 | -15 | -15 | N/A |
| 6/30/2022 | N/A | -18 | -17 | -17 | N/A |
| 3/31/2022 | N/A | -20 | -20 | -20 | N/A |
| 12/31/2021 | N/A | 97 | -25 | -25 | N/A |
| 9/30/2021 | N/A | 24 | -28 | -28 | N/A |
| 6/30/2021 | N/A | 9 | -31 | -31 | N/A |
| 3/31/2021 | N/A | -8 | -33 | -33 | N/A |
| 12/31/2020 | N/A | -113 | -34 | -34 | N/A |
| 9/30/2020 | N/A | -87 | -37 | -37 | N/A |
| 6/30/2020 | N/A | -78 | -40 | -40 | N/A |
| 3/31/2020 | 1 | -65 | -42 | -42 | N/A |
| 12/31/2019 | 1 | -85 | -45 | -44 | N/A |
| 9/30/2019 | 2 | -45 | -46 | -46 | N/A |
| 6/30/2019 | 2 | -46 | -47 | -47 | N/A |
| 3/31/2019 | 0 | -51 | -51 | -51 | N/A |
| 12/31/2018 | 1 | -60 | -52 | -52 | N/A |
| 9/30/2018 | 1 | -63 | -52 | -52 | N/A |
| 6/30/2018 | 1 | -66 | -52 | -52 | N/A |
| 3/31/2018 | 1 | -71 | -53 | -52 | N/A |
| 12/31/2017 | 1 | -66 | -55 | -55 | N/A |
| 9/30/2017 | 16 | -50 | -39 | -39 | N/A |
| 6/30/2017 | 16 | -49 | -38 | -38 | N/A |
| 3/31/2017 | 16 | -41 | -33 | -33 | N/A |
| 12/31/2016 | 16 | -38 | N/A | -28 | N/A |
| 9/30/2016 | 1 | -51 | N/A | -42 | N/A |
| 6/30/2016 | 1 | -50 | N/A | -43 | N/A |
| 3/31/2016 | 1 | -49 | N/A | -43 | N/A |
| 12/31/2015 | 0 | -49 | N/A | -43 | N/A |
| 9/30/2015 | 0 | -49 | N/A | -44 | N/A |
| 6/30/2015 | 0 | -47 | N/A | -40 | N/A |
| 3/31/2015 | 0 | -42 | N/A | -36 | N/A |
| 12/31/2014 | 0 | -39 | N/A | -31 | N/A |
| 9/30/2014 | 0 | -34 | N/A | -26 | N/A |
| 6/30/2014 | 0 | -29 | N/A | -23 | N/A |
| 3/31/2014 | 0 | -26 | N/A | -21 | N/A |
| 12/31/2013 | 0 | -21 | N/A | -17 | N/A |
| 9/30/2013 | 0 | -21 | N/A | -17 | N/A |
| 6/30/2013 | 0 | -21 | N/A | -17 | N/A |
| 3/31/2013 | 0 | -19 | N/A | -18 | N/A |
| 12/31/2012 | 0 | -22 | N/A | -20 | N/A |
| 9/30/2012 | 0 | -26 | N/A | -19 | N/A |
애널리스트 미래 성장 예측
수입 대 저축률: Insufficient data to determine if ACGN's forecast earnings growth is above the savings rate (2.2%).
수익 vs 시장: Insufficient data to determine if ACGN's earnings are forecast to grow faster than the US market
고성장 수익: Insufficient data to determine if ACGN's earnings are expected to grow significantly over the next 3 years.
수익 대 시장: ACGN is forecast to have no revenue next year.
고성장 수익: ACGN is forecast to have no revenue next year.
주당 순이익 성장 예측
미래 자기자본 수익률
미래 ROE: Insufficient data to determine if ACGN's Return on Equity is forecast to be high in 3 years time